ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

zolacabtagene autoleucel

Also written as “CC-97540” and “BMS-986353”.

Its studies are mostly in Scleroderma, Systemic · Multiple Sclerosis · Lupus Erythematosus, Systemic · Lupus Nephritis · Anemia, Hemolytic, Autoimmune, led by Bristol-Myers Squibb.

Drug pageZolacabtagene autoleucel: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 9, 20266 company-led studies, 5 open or runningNext primary completion: Jul 15, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb65 open or runningphase 3since Jan 9, 2026Jan 14, 2020Jul 15, 2027phase 1 · NCT06220201
  • Named in Bristol-Myers Squibb’s own pipeline as zola-cel, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 14, 2020First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT04231747 · 24 enrolled · United States, Canada
  2. May 11, 2023Phase 1 study in Lupus Erythematosus, SystemicNCT05869955 · 270 enrolled · United States, Belgium, France and more
  3. Jan 4, 2024Phase 1 study in Multiple SclerosisNCT06220201 · 120 enrolled · United States, Belgium, France and more
  4. Feb 13, 2025Named zolacabtagene autoleucelINNProposed as its International Nonproprietary Name in WHO's List 132 · before, CC-97540, BMS-986353
  5. May 30, 2025Phase 2 study in Lupus Erythematosus, SystemicNCT07015983 · 89 enrolled · United States, Argentina, Austria and more
  6. Jan 9, 2026Phase 3 study in Scleroderma, SystemicPhase 3 reachedNCT07335562 · 92 planned · United States, Belgium, Canada and more
  7. May 18, 2026Phase 2 study in Anemia, Hemolytic, AutoimmuneNCT07603557 · 52 planned · United States, Denmark, Germany and more

Ahead

  1. Jul 15, 2027Primary completion: phase 1 study in Multiple SclerosisNCT06220201
  2. May 17, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07015983
  3. Aug 29, 2028Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT05869955
  4. Nov 14, 2028Primary completion: phase 3 study in Scleroderma, SystemicNCT07335562

TargetBeta

“A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, zolacabtagene autoleucel specifical…”NCIt, read by Claude
“A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, ”NCIt, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
rapcabtagene autoleucelNovartisphase 28

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07603557Anemia, Hemolytic, Autoimmune · United States, Denmark, Germany and more2Not yet recruitingMay 6, 203052
NCT07335562Scleroderma, Systemic · United States, Belgium, Canada and more3Not yet recruitingNov 14, 202892
NCT07015983Lupus Erythematosus, Systemic · United States, Argentina, Austria and more2Active, not recruitingMay 17, 202889
NCT06220201Multiple Sclerosis · United States, Belgium, France and more1Active, not recruitingJul 15, 2027120
NCT05869955Lupus Erythematosus, Systemic · United States, Belgium, France and more1Active, not recruitingAug 29, 2028270
NCT04231747Lymphoma, Non-Hodgkin · United States, Canada1CompletedFeb 1, 202424

How it is read

Names in the registry

  • “CC-97540”, 4 entries
  • “BMS-986353”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.